MAY 0 3 2005

Sheet 1 of 2

FORM	PIE	71449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY, DOCKET NO.: OC01617K1			APPLICATION NO.: 10/776, 988			
PATENT AND TRADEMARK OFFICE OCO1617K1 10/776, 988 RADEMARY INFORMATION DISCLOSURE STATEMENT APPLICANT: BY APPLICANT Timothy J. Guzi et al.												
		(U	se several sheets	()	FILING DATE: 02/11/2004			GROUP LY				
			•	U.S. PAT	ENT DOCU	MENTS			. '			
EXAMINER INITIAL			DOCUMENT NUMBER	DATE	NAME		CL	ASS			FILING DATE IF	
7		AA	5,571,813	11/05/1996	Rühte	er et al.		I				
	I_{-}	AB	5,602,136	02/11/1997	Rühte	er et al.						
	oxdot	AC	5,602,137	02/11/1997		er et al.						
		AD	5,688,949	11/18/1997		e et al.		L				
		AE	5,707,997	01/13/1998		i et al.	1/					
	_	AF	5,919,815	07/06/1999		ey et al.	11		1_1		ļ	
	<u> </u>	AG	6,040,321	03/21/2000		et al.	+		\sqcup			
		AH	6,107,305	08/22/2000		et al.	+					
	ļ.,	Al	6,191,131	02/20/2001		et al.	₩		ļļ			
—∧	<u>/</u>	AJ.	6,262,096	07/17/2001		et al.	1-1					
		AK ·	6,413,974	07/02/2002	Dumo	nt <i>et al.</i>	1-1		└		L	
			F	OREIGN PA	ATENT DOC	UMENTS	·					
			DOCUMENT	DATE	COUNTRY		CLA	SS	SUE	}-	TRANS	LATION
			NUMBER		•				CLA	SS	YES	NO
4	<u> </u>	AL	DE 102 23 917 A1	11/12/2003	Geri	many						
		AM	EP 0 628 559	04/03/2002	Eui	горе						
		AN	EP 1 334 973	08/13/2003	Eui	rope						
			WO 02/22610	03/21/2002	P	CT	1					
		AP	WO 02/40485	05/23/2002	P	CT.	T -					
		PΑ	WO 02/50079	06/27/2002	. P	CT ·	\top					
	/	AR	WO 03/091256 A1	11/06/2003		CT						
U		AS	WO 95/35298	12/28/1995	P	CT						
		OTH	HER DOCUMENT	S (Including	Author Title	e Date Perl	inen	t Pa	aes	Ft	c 1	•
		AT	Vesely et al., "Inhibit	on of Cyclin-D	enendent Kina	ses by Purine A	Anain	TUPS	- F.,	<u>, _,</u>	Biocher	,
Y_			(1994), 224: 771-788	3.	-p	,		9000	,			"]
	AU Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis								thesis.	X-rav		
].			Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , (2002), 45: 3905-3927.									
		AV	Meltey et al., "Aloising	es, a New Far	nily of CDK/GS	K-3 inhibitors.	SAR	Stu	IV. C	rvsta	Struct	ure in
- [Complex with CDK2	Enzyme Sele	ctivity, and Cell	ular Effects", J	. Med	. Ch	вт. (200:	3), 46(2)	: 222-
		AW	236.									
- 1		^**	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-									
-+		AX	a)pyrimidines", J. Med. Chem. (1977), 20(2): 298-299.									
1		~	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopindol, a Novel Cyclin-Dependent Kingse Inhibitor in Patients with Refrectors Needlegge", Journal of Citators Opening (Sentember 1997)									
		·	Kinase Inhibitor, in Patients with Refractory Neoplasms*, Journal of Clinical Oncology (September 1998), 16(9): 2986-2999.									
N	/	AY	Meijer et al., "Bioche	mical and Cell	ular Effects of I	Roscovitine a l	Poten	tano	Sel	activ	e Inhihit	or of
4			the Cyclin-Dependen	Kinases CDC	2. CDK2 and	CDK5". Fur. J.	Bioch	iem.	(199	71. 2	43:527-	536
EXAMI	NER		10 / //	/		ONSIDERED		/	1.00	. /: =		
										l		
		m				4/14		51				1
EXAM	INE	R: Ini	lial if reference consi	dered, whether	or not citation	is in conforma	nce w	rith N	1PEP	609	; Draw	line
hrough citation if not in conformatice and not considered. Include copy of this form with next communication to												

FORM PTO	1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.:	APPLICATION NO.: 10/776,988							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT APPLICANT: Timothy J. Guzi et al.											
	(U	se several sheets if necessary)	FILING DATE: 02/22/2004	GROUP							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
AZ Bible et al., "Cytotoxic Synergy Between Flavopindol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Research (Augus 15, 1997), 57: 3375-3380.											
	BA Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin										
	Il Receptor Antagonists: Pyrazolo[1,5-a]pyrimidine Derivatives*, Chem. Pharm. Bull. (1999), 47(7): 928-938.										
	88	Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)									
	ВС	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted									
		Pyrazolo[1,5-a]pyrimidines.", Chem. Pharm. Bull (1962), 10: 620-626.									
	BD Cai et al., "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", J. Med. Chem. (1997), 40:3679-3686.										
	BE Bruce L. Finkelstein, "Regioselective Lithlation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and										
1{	Pyrazolo[1,5-a]pyridine", J. Org. Chem., (1992), 57: 5538-5540.										
	BF Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage",										
	-	Journal of Cell Science (1995), 108: 2897-2904.									
	BG	Shiota et al., "Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-a]pyrimidine", J. Org. Chem. (1999), 64: 453-457.									
W.	BH Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-as- triazines", Journal of Medicinal Chemistry, (1976), 19(4): 517-520.										
	BI	and the state of the decimal of the state of	1. 13(4). 311-320.								
EXAMINER 1/1 / DATE CONSIDERED											
1 Gu 1/1/67											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to											
applicant.	applicant.										